⚠️ Combining ibogaine with certain medications — including common antidepressants, methadone, and long-acting opioids — has caused fatal cardiac events and serotonin syndrome. This washout guide is non-negotiable, not optional preparation. Do not self-manage discontinuation of any psychiatric or opioid medication without medical supervision.

Ibogaine is a powerful serotonergic and cardiac-active compound. It prolongs the heart's QTc interval, inhibits multiple cytochrome P450 enzymes (especially CYP2D6 and CYP3A4), and can cause lethal serotonin toxicity when combined with certain medications. A structured medication washout — sometimes called a "clearance period" — is one of the most critical safety steps before any ibogaine session. Reputable clinical programs will not administer ibogaine until confirmed washout is complete and, in many cases, until a 12-lead ECG and blood panel confirm readiness (Litjens & Brunt, 2016).

Why Medication Interactions Are Deadly With Ibogaine

Ibogaine and its primary active metabolite noribogaine share three overlapping danger mechanisms:

  • QTc prolongation: Ibogaine blocks hERG potassium channels, extending cardiac repolarization. Any co-medication that also prolongs QTc (methadone, SSRIs like citalopram, antipsychotics, certain antibiotics) compounds this effect and can trigger Torsades de Pointes — a potentially fatal arrhythmia (Koenig & Hilber, 2015).
  • Serotonin syndrome: Ibogaine elevates synaptic serotonin. Adding SSRIs, SNRIs, MAOIs, tricyclic antidepressants, tramadol, or lithium risks hyperthermia, rigidity, seizure, and death.
  • CYP2D6 inhibition: Ibogaine is itself metabolized by CYP2D6 and inhibits the enzyme simultaneously, causing unpredictable plasma spikes of co-administered drugs and of ibogaine itself. This is why standard pharmacokinetic dosing calculations break down.

A 2023 review of ibogaine-associated fatalities identified that a significant proportion involved either concurrent opioid use (especially methadone) or undisclosed psychiatric medication (Zelfand et al., 2023).

Medications That Are Absolute Contraindications

The following drug classes represent hard stops — ibogaine should not be administered until these are fully cleared and the washout period has elapsed. Most established clinical protocols (including the Stanford Ibogaine Study protocol and Global Ibogaine Therapy Alliance guidelines) treat these as non-negotiable.

Methadone — Minimum 2–4 Week Washout (Often Longer)

Methadone is responsible for more ibogaine-associated deaths than any other single drug class. It is both a potent QTc prolonger and a long-acting opioid with a half-life of 24–36 hours — but in some individuals, over 60 hours. Transition to a short-acting opioid (such as morphine sulfate or oxycodone) under medical supervision is required well in advance. Some protocols require methadone blood levels of zero confirmed by lab test before proceeding. There is no safe "low dose" of methadone to combine with ibogaine.

SSRIs (Selective Serotonin Reuptake Inhibitors)

Includes: fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), citalopram (Celexa), paroxetine (Paxil), fluvoxamine (Luvox).

Risk: Serotonin syndrome + QTc prolongation (especially citalopram and escitalopram). Fluoxetine has a half-life of 1–6 days and its active metabolite norfluoxetine has a half-life of 4–16 days, requiring a minimum 5-week washout. Other SSRIs typically require 4–6 weeks. CYP2D6 inhibition by paroxetine may persist beyond the drug's own clearance.

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

Includes: venlafaxine (Effexor), duloxetine (Cymbalta), desvenlafaxine (Pristiq), levomilnacipran (Fetzima).

Risk: Serotonin syndrome. Standard washout: 2 weeks minimum for most SNRIs; duloxetine may require longer due to CYP2D6 interaction. Discontinuation must be tapered medically — abrupt SNRI cessation causes severe withdrawal.

MAOIs (Monoamine Oxidase Inhibitors)

Includes: phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Emsam), isocarboxazid (Marplan), and the antibiotic linezolid (weak MAOI activity).

Risk: Potentially fatal serotonin syndrome and hypertensive crisis. Washout: minimum 14 days for irreversible MAOIs; selegiline patch may require longer. Irreversible MAOIs inhibit the enzyme permanently — new enzyme synthesis takes ~2 weeks.

Tricyclic Antidepressants (TCAs)

Includes: amitriptyline, nortriptyline, imipramine, clomipramine, desipramine.

Risk: Both QTc prolongation and serotonin syndrome risk. CYP2D6 dependency creates dangerous plasma level spikes. Washout: 2–4 weeks depending on half-life. Medical taper required.

Antipsychotics

Includes: haloperidol, quetiapine (Seroquel), risperidone, olanzapine, ziprasidone, aripiprazole.

Risk: Additive QTc prolongation. Ziprasidone and haloperidol carry the highest risk. Washout: 2–4 weeks depending on the specific agent. Note: many people using antipsychotics for schizophrenia or bipolar disorder with psychotic features should not pursue ibogaine at all — a contraindication beyond timing.

Lithium

Risk: Ibogaine can cause fluid loss through sweating and vomiting, raising lithium to toxic levels. Lithium also lowers seizure threshold. Washout: minimum 2 weeks with confirmed serum level clearance.

Long-QT Implicated Drugs

The following individually prolong QTc and become dangerous in combination with ibogaine: azithromycin, clarithromycin, ciprofloxacin, levofloxacin, ondansetron (Zofran), domperidone, hydroxychloroquine, and certain antihistamines (terfenadine, astemizole — now withdrawn but informative). Check all current medications against the CredibleMeds QTDrugs List before any ibogaine treatment.

High-Risk Medications Requiring Medical Review

These are not automatic contraindications in all protocols but require physician assessment, ECG review, and often washout before ibogaine:

  • Buprenorphine (Suboxone, Subutex): Long-acting partial opioid agonist. Half-life 24–72 hours. Many protocols require transition to short-acting opioids 5–7 days before treatment, or at minimum 24–48 hours off buprenorphine. Unlike methadone, buprenorphine has less QTc risk, but incomplete opioid receptor occupancy creates unpredictable interactions with ibogaine's kappa-opioid activity. Some newer clinical programs manage buprenorphine transitions within 24 hours under medical supervision — this varies by protocol.
  • Tramadol: Both a weak opioid and a serotonin-norepinephrine reuptake inhibitor. Dual serotonin syndrome and seizure risk. Minimum washout: 5–7 days.
  • Stimulants (amphetamine salts, methylphenidate): Cardiovascular strain and serotonin interaction risk. Typically held for 48–72 hours minimum, though some protocols extend to 1 week.
  • Benzodiazepines: Not a serotonin or QTc risk, but tolerance and dependence make abrupt cessation dangerous (seizure risk). Do not stop benzodiazepines abruptly. Taper under medical supervision well in advance — timeline depends on dose and duration of use. Some protocols allow short-acting benzodiazepines as emergency rescue agents during an ibogaine session, but not pre-treatment loading.
  • Gabapentin / Pregabalin: Lower risk profile but requires physician review. Abrupt cessation can cause withdrawal seizures in dependent users.
  • Beta-blockers and antiarrhythmics: May mask compensatory heart rate responses during ibogaine. Discuss with treating cardiologist. Flecainide and amiodarone are absolute contraindications.
  • Cannabis (THC): May potentiate anxiety and cardiovascular strain. Most protocols recommend stopping 24–48 hours prior. CBD: lower risk but may inhibit CYP enzymes — stop 48 hours prior.
  • Alcohol: Cease completely 24–48 hours before treatment minimum. Active alcohol withdrawal is a medical emergency and a contraindication to ibogaine.

Generally Lower-Risk Medications (Still Disclose)

Always disclose everything to your clinical team. The following are typically lower risk but should be reviewed:

  • Thyroid medications (levothyroxine) — usually continued
  • Blood pressure medications — reviewed case by case
  • Vitamins and supplements — note that St. John's Wort is an absolute contraindication (MAOI and CYP3A4 inducer combined)
  • Anticoagulants (warfarin, apixaban) — require physician review; ibogaine may affect metabolism
  • Proton pump inhibitors (omeprazole) — generally low concern

The Washout Protocol Process Step by Step

  1. Submit a complete medication list — including doses, frequency, and how long you've been taking each drug — to your ibogaine clinic at least 4–6 weeks before your planned treatment date.
  2. Get a 12-lead ECG — baseline QTc should be under 450ms in men and under 460ms in women according to most clinical protocols. Some programs use a 440ms cutoff. A QTc above 500ms is a contraindication in virtually all protocols (Litjens & Brunt, 2016).
  3. Work with your prescribing physician — never stop psychiatric medications, benzodiazepines, or methadone without medical supervision. Inform them of your plans so they can manage the taper safely.
  4. Confirm washout with lab testing — reputable programs require urine and/or blood toxicology screens confirming clearance of methadone, SSRIs, and other high-risk drugs before proceeding.
  5. Re-submit your medication list at the time of treatment, including anything taken in the prior 48 hours (including over-the-counter medications).
  6. Do not take any new medication during the washout period without clearing it first with both your prescribing physician and the ibogaine clinical team.

Consequences of Ignoring Washout Protocols

This is not a theoretical concern. Documented outcomes of proceeding with inadequate washout include:

  • Cardiac arrest from Torsades de Pointes: Multiple case reports link methadone co-administration with ibogaine-associated cardiac death. A 2012 case series documented three deaths in individuals who had not completed methadone clearance (Alper et al., 2012).
  • Serotonin syndrome: Cases involving concurrent SSRI use and ibogaine have resulted in hyperthermia above 41°C, rhabdomyolysis, and death.
  • Seizures: Inadequate benzodiazepine taper prior to ibogaine removes a protective mechanism and increases seizure risk during the extended ibogaine experience (which can last 24–36 hours).
  • Prolonged and intensified experience: CYP2D6 inhibition from residual SSRIs can push ibogaine plasma levels dangerously high, extending the duration and intensity of the experience far beyond predicted parameters.

Frequently Asked Questions

No. There is no established safe low dose of SSRIs, SNRIs, or MAOIs concurrent with ibogaine. Serotonin syndrome risk is not purely dose-dependent — the mechanism involves ibogaine's own serotonin activity interacting with any reuptake inhibition, regardless of antidepressant dose. Fluoxetine additionally inhibits CYP2D6 even at sub-therapeutic doses, altering ibogaine metabolism unpredictably. All reputable clinical protocols require full cessation and confirmed washout.
Protocols vary. Many programs require you to transition off buprenorphine to short-acting opioids (typically morphine or oxycodone) several days before ibogaine, then allow those to clear 12–24 hours before treatment. Some newer medically supervised programs manage buprenorphine transitions within a shorter window. What no reputable program should do is administer ibogaine while you are actively dosed on buprenorphine without a structured transition plan, as high buprenorphine receptor occupancy reduces ibogaine's anti-addictive efficacy and the interaction is not fully characterized. Confirm your clinic's specific buprenorphine protocol in writing before enrolling.
Responsible clinics use a combination of: (1) urine toxicology screening for opioids, methadone, benzodiazepines, and stimulants; (2) blood panels for methadone levels (target: zero or undetectable); and (3) repeat 12-lead ECG on the day of treatment to confirm QTc is within acceptable range. Some programs also use plasma SSRI levels for patients on long-half-life drugs like fluoxetine. If a clinic does not perform pre-treatment toxicology and ECG, treat that as a serious red flag regarding their safety practices.
This is genuinely dangerous, not a bureaucratic concern. Undisclosed medications are a leading contributing factor in ibogaine-associated deaths and serious adverse events. If you realize you forgot to disclose something — even an over-the-counter medication like a decongestant or an herbal supplement (especially St. John's Wort) — tell your clinical team immediately, even on the day of treatment. A responsible clinic will postpone rather than proceed with unknown risk factors. The discomfort of rescheduling is far preferable to a cardiac emergency during a 24-hour hallucinogenic experience where emergency intervention is complicated.
Abrupt SSRI cessation — especially of paroxetine, venlafaxine, or duloxetine — causes a recognized discontinuation syndrome: electric "brain zaps," dizziness, nausea, intense emotional dysregulation, and in some cases suicidal ideation. This is both medically problematic and complicates ibogaine treatment planning. The correct approach is a medically supervised taper over 2–8 weeks (depending on the drug and your dose) coordinated with your prescribing physician and your ibogaine clinic simultaneously. Start this process as early as possible — ideally 6–10 weeks before your planned treatment date for long-acting SSRIs like fluoxetine.
This is the clinical team's responsibility, not yours. A properly equipped ibogaine facility should have on-site: IV access capability, cardiac monitoring equipment, a defibrillator, parenteral benzodiazepines (for seizure rescue), and ideally atropine or other cardiac emergency medications. Ask your clinic directly what emergency medications and equipment they have on-site. If they cannot answer clearly or seem dismissive of the question, that is a significant safety concern. The Global Ibogaine Therapy Alliance (GITA) clinical guidelines provide a recommended emergency preparedness checklist that reputable programs reference.

Key Resources

Informational only. Not medical advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.